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ABSTRACT: 
Background: Measurement of objective response to chemotherapy using imaging modalities is sometimes 
difficult in pancreatic cancer (PC). We aimed to verify whether monitoring of serum tumor markers 
(TMs), namely carcinoembryonic antigen, CA19-9, DUPAN-2, SPan-1, can facilitate earlier confirmation 
of treatment failure. Methods: Monitoring of serum TMs and computed tomography were performed 
every 4 weeks until progression of disease in 90 patients with PC undergoing gemcitabine therapy. In 
Group A (January 2006- October 2007), we analyzed the fluctuation rates of TMs with high pretreatment 
positive rates, and defined the criteria of progressive disease under TM monitoring (TM-PD). In Group B 
(November 2007- October 2008), we calculated the time to progression (TTP) under this TM-PD criteria, 
which was compared with the TTP under the RECIST criteria. Results: CA19-9 and SPan-1 had the 
highest pretreatment positive rates: 83% and 90%, respectively. In Group A (CA19-9, n = 38; SPan-1, n = 
36), TM-PD criteria were defined as follows: fluctuation rates were ≥25% for a month or ≥10% for 2 
consecutive months in CA19-9, and ≥10% for a month in SPan-1. In Group B (CA19-9, n = 18; SPan-1, n 
= 17), under these criteria, one-month earlier confirmation of treatment failure was feasible in 61% by 
CA19-9 and 59% by SPan-1. Furthermore, the combination could facilitate this determination in 72% 
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(35/49), significantly better than CA19-9 alone (P = 0.004). Conclusion: Monitoring of serum CA19-9 
and SPan-1 is helpful for earlier confirmation of treatment failure during gemcitabine therapy in PC. 
Keywords: Pancreas; Tumor marker; Gemcitabine; Diagnosis  
Abbreviations: CEA, carcinoembryonic antigen; CT, computed tomography; PD, progressive disease; 
RECIST, Response Evaluation Criteria in Solid Tumor; TM, tumor marker; TTP, time to tumor 
progression; TM-PD, progressive disease under tumor marker monitoring; TM-TTP, time to progression 
of tumor marker; ULN, upper limit of normal; 
INTRODUCTION 
Pancreatic cancer is the fourth-leading cause of cancer-related mortality in the United States and the fifth 
in Japan. Symptoms of pancreatic cancer include anorexia, weight loss, weakness, fatigue, abdominal 
pain, and nausea. The nonspecific and mild nature of these initial symptoms often results in delayed 
diagnosis; consequently, 80% or more of patients initially present with locally advanced or metastatic 
disease.1 Therefore, systematic chemotherapy using gemcitabine or other drugs2 is considered the 
treatment of choice for patients with this morbidity. Despite the low objective response rate, gemcitabine 
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improves survival and provides a clinical benefit. However, the median survival time is 5.7 months and 
the one-year survival rate 18%.3 Recently, a Phase III study ‘CONKO-003’ provided at first time evidence 
for the benefit of second-line chemotherapy as compared to best supportive care alone for patients with 
pancreatic cancer.4 To facilitate early second-line chemotherapy induction, earlier detection of treatment 
failure of the first-line chemotherapy is mandatory. Furthermore, earlier discontinuation may limit 
adverse effects, thereby improving quality of life, and reduce unnecessary costs. 
Currently, objective measurement of response to chemotherapy using the Response Evaluation Criteria in 
Solid Tumors (RECIST)5 is formally available. However, these criteria are sometimes difficult to apply to 
pancreatic cancer, which comprises inflammatory cells and fibrotic tissue as well as malignant cells.6 
Under a computed tomography (CT) scan, it is difficult to discriminate the tumor component from 
others.7 In addition, the evaluation of progressive disease for non-measureable lesions such as ascites, 
pleural effusion, and pericardiac effusion, is subjective and equivocal.  
Tumor markers (TMs) have often been identified as surrogate markers. For example, a decrease in 
CA19-9 during chemotherapy has been reported to be useful for predicting the outcome of patients with 
pancreatic cancer in some retrospective studies.8-15 We expected that use of such a TM may enable us to 
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detect early treatment failure of pancreatic cancer during chemotherapy, which has not been established. 
The aim of this study is to verify whether monitoring of serum TMs, such as carcinoembryonic antigen 
(CEA), CA19-9, DUPAN-2, and SPan-1, can facilitate earlier detection of treatment failure during 
chemotherapy for pancreatic cancer than evaluation with the RECIST criteria. 
PATIENTS AND METHODS 
Patients 
The patients analyzed in this study were enrolled in the randomized controlled trial UMIN ID 974, 
entitled “A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic 
cancer: a randomized phase II study to evaluate toxicity and dose intensity”.16 Therefore, all patients had 
unresectable, histologically or cytologically proven, locally advanced or metastatic pancreatic 
adenocarcinoma. Other eligibility criteria included no prior therapy, Karnofsky Performance Status ≥50%, 
age between 20 and 80 years, life expectancy of more than 2 months, and adequate organ function defined 
as white blood cell count ≥3000/mm3, neutrophils ≥1500/mm3, platelets ≥100000/mm3, hemoglobin ≥9.0 
g/dl, total bilirubin ≤2.0 mg/dl (or ≤3.0 mg/dl if biliary drainage was present), AST and ALT ≤2 times the 
upper limit of normal (ULN) (or ≤5 times the ULN if liver metastasis was present), and creatinine ≤ the 
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ULN. The number of patients enrolled in this original study was 90.  
All patients understood the nature of the study, and written informed consent was obtained from all of 
them. The local ethics committee approved this treatment protocol. In addition, all patients agreed with 
the analysis of their clinical data including this study. 
Chemotherapy and Assessment of Efficancy and Toxicity 
Patients were randomly assigned to either the 4-week or 3-week schedule of gemcitabine monotherapy. 
For the 4-week schedule, gemcitabine was administered intravenously at 1000 mg/m2 as a 30-min 
infusion on days 1, 8 and 15 of a 28-day cycle, whereas in the 3-week schedules, gemcitabine was 
administered at the same dose on days 1 and 8 of a 21-day cycle. Cycles were repeated every 4 or 3 
weeks, respectively. Toxicity was graded according to the National Cancer Institute common toxicity 
criteria, version 3.0. If grade 3-4 hematological toxicity or grade 2-4 non-hematological toxicity was 
noted, administration was postponed for a week. The gemcitabine dose was then reduced by 200 mg/m2 
from the previous dose, with a minimum dose of 400 mg/m2. Once a dose reduction was required, 
reescalation of dose was not allowed. A delay in the cycle of up to 2 weeks during one course was 
allowed when grade 2-4 hematological toxicity was recorded on day 1 of each cycle. When recovery from 
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treatment-related toxicity required more than 2 weeks, the gemcitabine treatment was stopped.  
A CT scan was performed at baseline and every 4 weeks during chemotherapy until objective findings of 
disease progression were noted. Tumor response (i.e. maximum response during treatment) was assessed 
according to the RECIST criteria every 4 weeks. In addition, clinically severe symptoms related with 
progressing cancer, such as aggravated general condition, uncontrollable pain and GI obstruction, were 
also regarded as progressive disease (PD), namely, clinical PD. Treatment decisions were based on these 
radiographic and clinical grounds, and not on serum TM concentrations. Treatment was continued for at 
least 2 months and until progression of disease, occurrence of unacceptable toxicity, or patient refusal. 
Patients who had unacceptable toxicity or refused therapy were excluded from this study. 
Tumor response by RECIST criteria 
Tumor response was categorized as complete response, partial response, stable disease, or PD by RECIST 
criteria.5 All patients with evidence of a complete response or partial response or stable disease on at least 
one occasion were considered to have unconfirmed response. Confirmed responses were those 
documented with a follow-up CT scan obtained 4 weeks or longer after the scan that documented the 
initial response. Time to tumor progression (TTP) was defined as the time from initial therapy to the first 
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objective documentation of tumor progression or clinically severe symptoms such as those described 
above. 
Serum tumor markers measurement 
Serum CEA, CA19-9, DUPAN-2, and SPan-1 were measured at baseline (on day 1 of first cycle of 
gemcitabine monotherapy) and every 4 weeks thereafter, on the same day of CT scan assessment. The 
CEA and CA19-9 were measured using an electrochemiluminescence immunoassay (ECLIA), DUPAN-2 
using an enzyme immunoassay (EIA), and SPan-1 using an immunoradiometric assay (IRMA) at all 
institutions. In addition, the ULN of CEA was 5 ng/ml, that of CA19-9 was 37 U/ml, that of SPan-1 was 
30 U/ml, and that of DUPAN-1 was 150 U/ml. Baseline and follow-up measurements for any given 
patient were performed at the same laboratory and by the same method. 
Evaluation 
Positive rates for each TM before initial chemotherapy were calculated in patients who were enrolled in 
this original study. TMs having values higher than the upper limit of normal were considered as indicators 
which should be investigated. After selecting some TMs with higher pretreatment positive rates than the 
others, we made the following analysis.  
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In the first series of the cases (January 2006- October 2007; Group A), we analyzed the fluctuation of TM 
ratios in relation to tumor responses. Specifically, the changes in each TM were calculated as the TM 
fluctuation ratio according to the following formula: (A / B) × 100 － 100, where A is the TM value of 
that day and B is the TM value of the one-month-before in each case. We calculated the median TM 
fluctuation ratio in the course of chemotherapy every 4 weeks until the recording of PD by tumor 
responses. We expected that an increase of the TM fluctuation ratio could become a sensitive indicator to 
predict the disease progression, and defined threshold value of this ratio on the basis of median TM 
fluctuation ratios at 1 and 2 months before PD under RECIST criteria by tumor responses. According to 
these methods, we defined this increase as PD under TM monitoring (TM-PD). Using this criterion, we 
calculated the time to progression of TM (TM-TTP), which was defined the time from initial therapy to 
documentation of TM-PD. Additionally, comparison of mean values and correlations were examined 
between conventional TTP by RECIST criteria and TM-TTP.  
In the subsequent series (November 2007- October 2008; Group B), we calculated TM-TTP by the 
TM-PD criterion defined in Group A, which was compared with the conventional TTP to investigate the 
possibility of the early prediction of gemcitabine failure. Furthermore, TM-TTP using two or more types 
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of TM was compared with the conventional TTP.  
In addition, median TM fluctuation ratios of selected tumor markers one month after initial chemotherapy 
by tumor responses were measured to support that their ratios reflected tumor progression. Overall 
survival was defined as the time from initial therapy to the date of either death or the last follow-up 
assessment.  
Statistical analysis 
Continuous data are presented as medians and ranges. Continuous variables were compared with 
Mann-Whitney U test. Frequency distribution was compared with Fisher’s exact test or the χ2 test. 
Pearson’s correlation coefficient was used to analyze the relationship between TTP and TM-TTP. Paired t 
test was used to compare between TTP and TM-TTP. Detection of treatment failure using the relationship 
between TTP and TM-TTP was evaluated by sign test. Survival analysis was assessed by the 
Kaplan-Meier method, and the survivals of Group A and Group B were compared using the log-rank test. 
All statistical analyses were performed with JMP 8.0.1 software (SAS Institute). A P-value <0.05 was 
considered statistically significant.  
RESULTS; 
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Positive rate for each TM 
The positive rate for each TM before induction of chemotherapy was 50% (45/90) for CEA, 83% (75/90) 
for CA19-9, 73% (59/81) for DUPAN-2, and 90% (73/81) for SPan-1, respectively. Nine of 90 patients 
were excluded from the SPan-1 and DUPAN-2 analyses as these markers had not been measured in these 
patients. From our results, since CA19-9 and SPan-1 had high positivity rates, we selected these two TMs 
for the subsequent analysis. 
Seventy-three of 90 patients (81.1%) received gemcitabine until progression of disease and 17 patients 
(18.9%) discontinued gemcitabine chemotherapy due to unacceptable toxicity or refusal of treatment. 
TM fluctuation ratio one month after initial chemotherapy by tumor responses in CA19-9 and 
SPan-1 
The median TM fluctuation ratio of CA19-9 one month after initial chemotherapy induction was 27% 
(interquartile range [IQR]: 0% to 112%) in PD patients, -12% (IQR: -41% to 25%) in stable disease and 
-68% (IQR: -73% to -22%) in partial response. Similarly, the median TM fluctuation ratio of SPan-1 one 
month after initial chemotherapy induction was 11% (IQR: -10% to 57%) in PD patients, -24% (IQR: 
-43% to 6%) in stable disease and -48% (IQR: -72% to -10%) in partial response. 
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Evaluation of disease progression from the CA19-9 fluctuation ratio 
The positive rate for CA19-9 before induction of chemotherapy among the patients who received 
gemcitabine until progression of disease was 83.6% (60/73). However, 56 of 60 patients (93.3%) were 
eligible for the analysis of CA19-9, because inadequate data accumulation regarding CA19-9 was noted 
in 4 patients (Table 1-A). In Group A (n = 38), the changes of the CA19-9 fluctuation ratio were 
demonstrated by tumor responses in Figure 1. From these results, the following fluctuation ratios were 
defined as TM-PD of CA19-9: the value was greater than 25% for a month or greater than 10% for 2 
consecutive months. Under this TM-PD criterion of CA19-9, mean TM-TTP was shorter than mean TTP 
(3.2 months vs. 4.6 months, respectively; P < 0.0001) and there was statistically significant correlation 
between TM-TTP and TTP in Group A (r = 0.798, P<0.001; Figure 3-A). Consequently, earlier 
confirmation of treatment failure was feasible in 61% (n = 11) of Group B (n = 18) by this criterion. 
Moreover, TM-PD of CA19-9 could facilitate significantly early confirmation of PD compared with PD 
under RECIST criteria in Group B (n = 16, 89%; P = 0.001; Table 2-A). In this study, median difference 
between TM-TTP and TTP was -1.0 (95%CI: -4.4- 1.0) months. 
Evaluation of disease progression from the SPan-1 fluctuation ratio 
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Positive rates for SPan-1 before initial chemotherapy were 88.1% (59/67) in the patients who received 
gemcitabine until progression of disease. Fifty-three of 59 patients (89.3%) were eligible for the analysis 
of SPan-1, because the data accumulation of six patients regarding SPan-1 was inadequate (Table 1-B). 
The changes of the SPan-1 fluctuation ratio in Group A (n = 36) are compared to tumor responses in 
Figure 2. From these results, TM-PD of SPan-1 was defined when its increase was greater than 10% for a 
month. Under this TM-PD criterion of SPan-1, mean TM-TTP was shorter than mean TTP (3.0 months vs. 
5.1months, respectively; P = 0.0007) and there was a statistically significant correlation between TM-TTP 
and TTP in Group A (r = 0.465, P = 0.006; Figure 3-B). Similarly, earlier confirmation of treatment failure 
by this criterion was feasible in 59% (n = 10) of Group B (n = 17). Furthermore, TM-PD of SPan-1 can 
facilitate the early confirmation of PD compared with PD under RECIST criteria in Group B (n = 13, 
77%; P = 0.049; Table 2-B). In addition, median difference between TM-TTP and TTP was -1.0 (95%CI: 
-3.5- 2.1) months.  
Evaluation of disease progression from the changes of a combination of CA19-9 and SPan-1 
Forty-nine of 73 patients (67%) who had both positive CA19-9 and SPan-1 before treatment were eligible 
for the analysis of combination of CA19-9 and SPan-1. We could make an earlier confirmation of 
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treatment failure in 72% of these patients using TM-PD criteria of both CA19-9 and SPan-1 (Table 3). 
Monitoring the combination of CA19-9 and SPan-1 could significantly facilitate earlier confirmation of 
PD compared with CA19-9 alone (P = 0.004).  
Discussion; 
This report is based on prospectively collected data from a cohort studied in a randomized controlled 
trial.16 Our data show that monitoring of serum CA19-9 and SPan-1 facilitates the earlier confirmation of 
the treatment failure by approximately one month in patients with pancreatic cancer during gemcitabine 
monotherapy. Furthermore, the combination of these two TMs ensures an increase in sensitivity. Certainly, 
one-month earlier confirmation may be short. However, their median TTP and median survival time were 
only 3.9 months and 8.2 months, respectively. Therefore, measuring the TTP-TM has a considerable 
clinical impact regarding the change of chemotherapy. 
CA19-9 is a tumor-associated antigen (first described by Koprowski et al.17) defined by a monoclonal 
antibody (1116 NS 19-9). Using a cutoff point of 37 U/ml as the ULN, the overall sensitivity of the assay 
in detecting pancreatic cancer was previously found to be approximately 80% with a specificity of 90%.18 
Furthermore, CA19-9 can change in association with tumor shrinkage or disease progression19, and 
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therefore changes in serum CA19-9 concentration during treatment often serve as a parameter for efficacy 
in the setting of a clinical trial.20 Regarding the usefulness of CA19-9 in patients receiving chemotherapy 
for advanced pancreatic cancer, a decrease in CA19-9 concentration has been proposed as a surrogate 
marker for survival in several retrospective studies9, 10, 11, 13, 15, 20, 21, and pretreatment CA19-9 values have 
been an independent predictor for survival in some other studies.12, 21, 22 However, in former studies, 
different definitions of CA19-9 response were used (between 20% and 50% decrease from pretreatment 
CA19-9). In this study, we made a definition of TM-PD for earlier confirmation of PD. As mentioned in 
the Patients and Methods section, we defined the criteria of TM-PD from the analysis of TM fluctuation 
ratio in Group A, which was applicable to the analysis of early confirmation of treatment failure in Group 
B. As a result, we found that the TM fluctuation ratio could serve an earlier detection marker of disease 
progression than RECIST criteria. 
Formerly, Rocha, Lima et al found a strong correlation between CA19-9 progression and TTP with 
CA19-9 progression preceding radiographic progression in most of their patients.23, 24 However, in their 
studies, CA19-9 was measured every 3 weeks and imaging studies were performed every 6 weeks. In our 
study, both the imaging study and the measurement of TMs were performed every 4 weeks. This is the 
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strength of our study because our data was feasible for detailed analysis. Therefore, our study supports a 
more precise correlation between TM-TTP and TTP.  
Ko et al reported that a rising/nondeclining CA19-9 appeared to be a clear indicator of early progressive 
disease and to correlate with very poor clinical outcomes.10 In our study, there were marked differences in 
the fluctuation of TMs between PD patients and disease-controlled, i.e. stable disease and partial response, 
patients during chemotherapy. The TM fluctuation ratio of CA19-9 one month after initial chemotherapy 
induction positively increased in most PD patients (74%; 17 of 23 patients). On the other hand, 
significantly fewer disease-controlled patients (34%; 11/33) had a positive fluctuation ratio (P = 0.003). 
Furthermore, the median TM fluctuation ratio of CA19-9 one month after initial chemotherapy induction 
was 27% (interquartile range [IQR]: 0% to 112%) in PD patients, -12% (IQR: -41% to 25%) in stable 
disease and -68% (IQR: -73% to -22%) in partial response, as mentioned in the Result section. 
Consequently, we can strongly support the fact that the positive fluctuation ratio of CA19-9 is a clear 
indicator of early disease progression.  
However, CA19-9 is a sialylated Lewisa (Le)a blood group antigen and individuals with Lewis-negative 
phenotype (lacking the Lewis antigen glycosyltranferase), who comprise approximately 5% of the 
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population, are unable to synthesize CA19-9.25 Kawa et al reported that DUPAN-2 was the precursor of 
CA19-9. Furthermore, they described that SPan-1 had an advantage over CA19-9 in the diagnosis of 
patients with Lewis-negative phenotype. In addition, the two markers had almost the same sensitivity for 
this malignancy.26 In our study, although DUPAN-2 was not used as a marker for assessment of early 
confirmation of disease progression, SPan-1 was found to be as useful a marker as CA19-9 for the 
evaluation of disease control. In fact, SPan-1 could detect treatment failure earlier than RECIST criteria in 
59% of the cases (Table 2-B). Moreover, in the case of the patients whose CA19-9 and SPan-1 values 
were both more than the baseline (81%: 66/81 in our study), we could make earlier confirmation of 
treatment failure by using TM-PD criteria of both CA19-9 and SPan-1 (72%, 35/49; Table 3). Accordingly, 
it is suggested that the monitoring of TMs during chemotherapy using our method can facilitate the 
change of treatment at an earlier point in the disease course. 
There are some limitations to our study. The number of patients was small and the two regimens using 
gemcitabine were included. However, we could demonstrate that there was statistically significant 
correlation between TM-TTP and TTP regarding CA19-9 and SPan-1 (r = 0.798, P<0.001; r = 0.465, P = 
0.006; respectively). As for the regimen, although cases with both 4-week and 3-week 
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gemcitabine-monotherapy schedules were included, the regimen was randomly allocated. Furthermore, in 
this trial, the 3-week regimen demonstrated the same efficacy and less toxicity compared with the 4-week 
regimen.16 Future larger studies are required to establish the role of CA19-9 and SPan-1 monitoring as a 
biomarker to confirm disease progression earlier in patients with pancreatic cancer treated with 
gemcitabine. 
In conclusion, monitoring of serum CA19-9 and/or SPan-1 is helpful for earlier confirmation of treatment 
failure in the treatment of patients with pancreatic cancer during gemcitabine monotherapy. The only 
chance to improve the prognosis of patients with pancreas cancer is changing the chemotherapeutic 
regimens when the first such regimen fails. Despite the existence of few promising second-line therapies, 
it is suggested that our findings will assist physicians in deciding on changes of regimen earlier in the 
progression of disease, when imaging findings are still equivocal.   
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Table 1-A. Patient Characteristics: CA19-9       
              
       
 Group A   Group B   P value 
              
       
No. of  patients 38   18   
Median age, years (range) 67 (42-75)   63 (55-74)   0.50
Gender      0.18
    Male, n 28   10  
    Female, n 10   8  
Baseline KPS        0.97
    100 %, n 16   7  
    90 %, n 18   9  
    80 %, n 4   2  
Stage (UICC criteria)       0.95
    III, n 4   2  
    IV, n 34   16  
Median basal CA19-9 value, U/ml (range)  859.3 (40.8-4237600)   3164 (52.5-381460)  0.38
Tumor response       0.77
    PR, n 5   4  
    SD, n 18   6  
    PD, n 15   8  
Reason for decision of progression of disease        0.83
    RECIST, n   33   16  
    Clinical PD, n    5   2  
Introduction of second-line chemotherapy      0.59
    PR, % 100   100  
    SD, % 83   100  
    PD, % 67   75  
    PR＋SD＋PD, % 79   89  
Median survival time, days (range) 239 (39-1026)   269 (97-821)  0.70
              
       
Abbreviations: KPS = Karnofsky performance status scale; PR = partial response; SD = stable disease;  
PD = progressive disease; RECIST = Response Evaluation Criteria in Solid Tumors.  
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Table 1-B. Patient Characteristics: SPan-1       
              
       
 Group A   Group B   P value 
              
       
No. of  patients 36   17   
Median age, years (range) 66 (42-75)   63 (55-74)   0.71
Gender      0.38
    Male, n 27   10   
    Female, n 9   7   
Baseline KPS        0.70
    100 %, n 15   6   
    90 %, n 17   10   
    80 %, n 4   1   
Stage (UICC criteria)       0.96
    III, n 5   3  
    IV, n 31   14  
Median basal SPan-1 value, U/ml (range)  314.4 (30.8-190000)   547.9 (81.7-8460.3)  0.37
Tumor response       0.92
    PR, n 6   3  
    SD, n 17   7  
    PD, n 13   7  
Reason for decision of progression of disease        0.52
    RECIST, n   30   16  
    Clinical PD, n    6   1  
Introduction of second-line chemotherapy      0.96
    PR, % 100   100  
    SD, % 88   100  
    PD, % 69   71  
    PR＋SD＋PD, % 83   88  
Median survival time, days (range) 246 (39-1026)  260 (136-560) 0.47
              
       
Abbreviations: KPS = Karnofsky performance status scale; PR = partial response; SD = stable disease;  
PD = progressive disease; RECIST = Response Evaluation Criteria in Solid Tumors. 
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Table 2-A.  Comparison of time to progression of tumor marker (TM-TTP) under TM-PD criterion of CA19-9 with time to tumor 
progression (TTP) under RECIST criteria in Group B 
           
 
 
Total        PD        SD       PR  
N = 18 
No. (%)  
N = 8 
No. (%)  
N = 6 
No. (%)  
N = 4 
No. (%)  
 
 
TM-TTP ≤ TTP 16 (89%) 7 (87%)  5 (83%) 4 (100%)  
                    * 
TM-TTP > TTP  2 (11%) 1 (13%) 1 (17%) 0 
      
Median difference 
between TM-TTP and TTP 
(95%CI); months 
－1.0 
 (－4.4- 1.0) 
－0.4  
(－1.3- 1.5) 
－1.0  
(－3.3- 1.0) 
－2.8  
(－5.7-－1.0) 
Comparison between 
median TM-TTP and 
median TTP 
† P = 0.738 
   
* P value was calculated by sign test.: P = 0.001 
† P value was calculated by median test.  
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Table 2-B.  Comparison of time to progression of tumor marker (TM-TTP) under TM-PD criterion of SPan-1 with time to tumor 
progression (TTP) under RECIST criteria in Group B 
           
 
 
Total        PD        SD       PR  
N = 17 
No. (%)  
N = 7 
No. (%)  
N = 7 
No. (%)  
N = 3 
No. (%)  
 
 
TM-TTP ≤ TTP 13 (77%) 5 (71%)  5 (71%) 3 (100%)  
                    * 
TM-TTP > TTP  4 (23%) 2 (29%) 2 (29%) 0 
      
Median difference 
between TM-TTP and TTP 
(95%CI); months 
－1.0 
 (－3.5- 2.1) 
0 
(－1.3- 3.3) 
－1.5 
(－3.3- 1.0) 
－3.0  
(－4.0-－2.0) 
Comparison between 
median TM-TTP and 
median TTP 
† P = 0.727 
   
* P value was calculated by sign test.: P = 0.049 
† P value was calculated by median test.  
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Table 3.  Comparison of time to progression of tumor marker (TM-TTP) using a combination of CA19-9 and SPan-1 with TM-TTP using CA19-9 
                                
Total        
N = 49 
PD       
N = 19 
SD 
N = 22 
PR 
N = 8 
TM-TTP < TTP 
30 → 35 6 → 10  17 → 18 7 → 7 
(61%) (72%) (31%) (53%)  (77%) (82%) (88%) (88%) 
 
   
TM-TTP = TTP 
12 → 9 10 → 7  2 → 2 0 → 0 
(25%) (18%) (34%) (37%)  (9%) (9%) 
TM-TTP > TTP  
7 → 5 3 → 2  3 → 2 1 → 1 
(14%) (10%) (16%) (10%)  (14%) (9%) (12%) (12%) 
                                 
Median difference 
between TM-TTP and 
TTP (95%CI); months  
 
－1.0 
(－3.9- 1.1) 
－1.0 
(－5.3- 0.5)
0 
(－1.0- 1.0)
0 
(－1.0- 0.5) 
 
－2.4 
(－4.5- 1.0)
－3.0 
(－6.7- 0.5)
－1.3 
(－4.1- 1.3)
－2.1 
(－5.1- 1.3) 
 
   
 
   
‡Comparison between 
median TM-TTP and 
median TTP 
P = 0.069 P = 0.105 P = 0.324 P = 0.104 P = 0.366 P = 0.016 P = 1 P = 0.133 
CA19-9  →  CA19-9 ＋SPan-1; n, (%)    
P values were calculated by sign test.: * P = 0.152,  † P = 0.004  
‡ P values were calculated by median test.  
 








